Related Experiment Video
Updated: Jun 29, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts
Abstract:
PARP1&2 enzymatic inhibitors (PARPi) are promising cancer treatments. But recently, their use has been hindered by unexplained severe anemia and treatment-related leukemia. In addition to enzymatic inhibition, PARPi also trap PARP1&2 at DNA lesions. Here, we report that unlike Parp2 -/- mice, which develop normally, mice expressing catalytically-inactive Parp2 (E534A, Parp2 EA/EA ) succumb to Tp53- and Chk2 -dependent erythropoietic failure in utero , mirroring Lig1 -/- mice. While DNA damage mainly activates PARP1, we demonstrate that DNA replication activates PARP2 robustly. PARP2 is selectively recruited and activated by 5'-phosphorylated nicks (5'p-nicks) between Okazaki fragments, typically resolved by Lig1. Inactive PARP2, but not its active form or absence, impedes Lig1- and Lig3-mediated ligation, causing dose-dependent replication fork collapse, particularly harmful to erythroblasts with ultra-fast forks. This PARylation-dependent structural function of PARP2 at 5'p-nicks explains the detrimental effects of PARP2 inhibition on erythropoiesis, revealing the mechanism behind the PARPi-induced anemia and leukemia, especially those with TP53/CHK2 loss.
Significance:
This work shows that the hematological toxicities associated with PARP inhibitors stem not from impaired PARP1 or PARP2 enzymatic activity but rather from the presence of inactive PARP2 protein. Mechanistically, these toxicities reflect a unique role of PARP2 at 5'-phosphorylated DNA nicks during DNA replication in erythroblasts.
Insights
Poly (ADP-ribose) polymerase inhibitors (PARPi) cause anemia by trapping inactive PARP2 at DNA replication sites, hindering DNA repair in erythroblasts. This reveals the mechanism behind PARPi-induced hematological toxicities.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective cancer therapies but cause severe anemia and leukemia.
- The exact mechanisms behind these PARPi-induced hematological toxicities remain unclear.
- PARP inhibitors are known to inhibit enzymatic activity and trap PARP1/2 at DNA lesions.
Approach:
- Investigated the role of PARP2 in erythropoiesis using catalytically inactive Parp2 mutant mice (E534A).
- Analyzed the recruitment and activation of PARP2 at 5'-phosphorylated nicks during DNA replication, particularly in relation to Okazaki fragment ligation.
- Examined the impact of inactive PARP2 on DNA ligase activity and replication fork stability in erythroblasts.
Key Points:
- Catalytically inactive PARP2 (E534A), but not its absence or active form, causes severe erythropoietic failure dependent on Tp53 and Chk2.
- PARP2 is robustly activated by DNA replication and selectively recruited to 5'-phosphorylated nicks, sites typically resolved by Lig1.
- Inactive PARP2 impedes Lig1 and Lig3-mediated ligation, leading to replication fork collapse, especially in erythroblasts with rapid replication forks.
Conclusions:
- The hematological toxicities of PARPi are caused by the presence of inactive PARP2 protein, not impaired enzymatic activity.
- Inactive PARP2 interferes with DNA ligation at Okazaki fragments, causing replication stress and cell death in erythroblasts.
- This study elucidates the mechanism of PARPi-induced anemia and leukemia, particularly in contexts of TP53/CHK2 loss.
Related Concept Videos
Abnormal Proliferation
Restarting Stalled Replication Forks
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
Long-patch Base Excision Repair
Negative Regulator Molecules

